摘要
目的探讨拉米夫定与苦参碱联用治疗儿童慢性乙肝的临床疗效。方法将曾经收治的78例慢性乙肝患儿随机分为对照1组,对照2组和治疗组,对照1组采用拉米夫定治疗,对照2组采用苦参碱治疗,治疗组采用拉米夫定与苦参碱联用治疗,用药6个月后将三组患者的HBV-DNA、HbeAg的转阴率以及丙氨酸氨基转移酶(ALT)水平进行比较。结果对照1组:HBV-DNA转阴率69.23%,HbeAg的转阴率65.38%,ALT恢复正常水平率69.23%;对照2组:HBV-DNA转阴率61.54%,HbeAg的转阴率57.69%,ALT恢复正常水平率65.38%;治疗组:HBV-DNA转阴率92.31%,HbeAg的转阴率80.77%,ALT恢复正常水平率84.62%,P<0.05,差异性显著,具有统计学意义。结论拉米夫定和苦参碱单用都具有治疗儿童慢性乙肝的作用,而两者联用更可以起到相互协同的作用,使治疗效果大大提高,值得临床应用和推广。
Objective To investigate lamivudine and matrine combined with the clinical efficacy of the treatment of children with chronic hepatitis B. Once admitted to our hospital 78 patients with chronic hepatitis B were randomly divided into a control group, the control group and the treatment group, control group 1 with lamivudine in the treatment and control group 2 with matrine treatment, the treatment group using the pull lamivudine and matrine combined with therapy, medication for six months will be three groups of patients of HBV-DNA naive, HBeAg seroconversion rate, and alanine aminotransferase （ALT） levels were compared. Results In the control group 1： HBV-DNA negative rate of 69.23% naive, HBeAg seroconversion rate of 65.38%, ALT reamed to normal levels 69.23%; control group 2： HBV-DNA negative rate of 61.54%, naive, HBeAg seroconversion rate of 57.69%, ALT returned to normal level of 65.38%; treatment group： I-IBV-DNA negative rate of 92.31%, naive, I-IBeAg rate of 80.77%, ALT normal level rate of 84.62%, P 〈0.05, the difference was significant, with statistical significance. Conclusion Lamivudine and matrine alone have a role in the treatment of children with chronic hepatitis B, can play the role of synergies between both associated with, and greatly improve the treatment effect, worthy of clinical application and promotion.
出处
《当代医学》
2013年第3期1-2,共2页
Contemporary Medicine
关键词
拉米夫定
苦参碱
儿童
慢性乙肝
Lamivudine
Matrine
Children
Chronic hepatitis B
